Cardarine (GW-501516) and the Psyche: Mood, Sleep, Anxiety

Cardarine (GW-501516) is usually discussed in the context of endurance and fat metabolism. The question of its effect on mood, sleep, and anxiety comes up less often, but it regularly arises in user discussions. The editorial team checked what science can say on this account, and honestly separated the known from the assumptions.

PPAR-delta in the nervous system

Peroxisome proliferator-activated receptors are nuclear receptors that regulate the expression of genes for lipid and glucose metabolism. Of the three subtypes, it is PPAR-delta that is most widely represented in the central nervous system: it is found in neurons of various parts of the brain, as well as in glial cells.

In the brain, lipid metabolism is of particular importance. Nervous tissue is rich in fatty acids, myelin sheaths consist predominantly of lipids, and the energy needs of neurons are very high. So it is not surprising that PPAR receptors participate in regulating the energetics of neurons and inflammatory processes in the brain, as noted in the review by Heneka and Landreth (2007).

In preclinical models, PPAR-delta agonists were studied as potentially neuroprotective agents: in individual animal experiments they reduced signs of neuroinflammation. However, these data were obtained in specific models of brain injury and do not concern the mood or behavior of a healthy person.

It is important to understand the limits of this information. The presence of a receptor in the brain does not mean that a drug taken orally necessarily reaches the brain in a significant concentration, and still less does it give grounds to predict a specific mental effect. The permeability of GW-501516 through the blood-brain barrier in humans has not been systematically studied.

What clinical studies say

There are few studies of GW-501516 in humans. The best known of them are the work of Sprecher et al. (2007) in healthy volunteers and the study by Risérus et al. (2008) in moderately obese men. Both lasted about two weeks and were aimed at lipids, insulin sensitivity, and fat oxidation.

None of these studies used validated scales to assess mood, anxiety, or sleep quality. Side effects were recorded in a general manner, and there are no reports of serious mental reactions in the published materials. But the short duration and small number of participants do not allow a conclusion about safety to be drawn.

So the honest answer to the question “how does Cardarine affect the psyche?” sounds like this: it is unknown. Any confident statements, both positive (“improves mood”) and negative, have no clinical data behind them.

Such a situation is typical of compounds whose development was stopped at an early stage. A detailed study of safety, including neuropsychiatric effects, is carried out in later phases, which GW-501516 did not reach.

Sleep and circadian rhythms

Fundamental research shows that nuclear receptors, including the PPAR family, are connected to the circadian clock. The work of Yang et al. (2006) in the journal Cell demonstrated that the expression of many nuclear receptors in metabolic tissues has a daily rhythm and links the work of the “clock” with metabolism.

From this it is sometimes concluded that PPAR-delta agonists “affect sleep”. However, the link of the receptor with circadian processes in the liver or adipose tissue is not the same as an effect on the regulation of sleep in the brain. There are no studies that would assess people’s sleep against the background of GW-501516.

In addition, in animal studies the activation of PPAR-delta changes the use of fuel by the muscles. Fan et al. (2017) showed that in mice this pathway conserves glucose during prolonged exercise, enhancing the use of fats. Such changes in metabolism could theoretically affect well-being, but a direct link with sleep has not been established.

Conclusion for practice: if sleep is disturbed against the background of any experimental compound, the first step is not to look for an explanation in the mechanisms but to stop the intake and see a doctor.

Where anxiety and insomnia come from

Despite the absence of clinical data, users not infrequently report anxiety, insomnia, or, on the contrary, a “rush of energy”. The editorial team believes that most such reports are explained not by the molecule itself but by the circumstances of use.

Firstly, Cardarine is often combined with other substances: stimulant-based fat burners, high doses of caffeine, SARMs, thyroid hormones. Any of these substances can cause anxiety and insomnia on its own.

• Stimulants:caffeine, synephrine, yohimbine, and similar substances directly worsen sleep and increase anxiety.
• Unknown composition:products of the illegal market may contain other compounds not indicated on the label.
• Energy deficit:a strict diet combined with intense training disrupts sleep and mood regardless of supplements.
• The expectation effect:belief in a “potent” drug is itself able to change well-being.

Secondly, the very circumstances — taking an unregistered substance with known data on carcinogenicity in animals — can cause anxiety about health. People who read about the drug’s history only after starting to take it not infrequently describe exactly this state.

Finally, product quality is a separate problem. Analyses of products sold as “research chemicals” have repeatedly revealed a discrepancy between the content and what was declared. Without laboratory analysis it is impossible to know what exactly a person is taking and, accordingly, what caused the symptoms.

Psychological risks of non-medical use

Besides the direct pharmacological action, there are behavioral risks. Taking experimental substances often becomes part of a broader pattern: the desire to “optimize” the body at any cost, the gradual addition of new compounds, ignoring the body’s signals.

Studies among users of physical-fitness enhancers describe a link between such behavior and dissatisfaction with one’s own body and muscle dysmorphia. This does not concern Cardarine specifically, but it is important for understanding why a person begins to take risky substances.

For athletes, an additional stressor is the risk of a positive doping test. GW-501516 is banned by WADA in section S4, and its metabolites are reliably detected. The consequences of disqualification for a career and psychological state can be severe.

If you notice in yourself pronounced anxiety, sleep disturbances, a depressed mood, or an obsessive preoccupation with appearance, it is worth seeing a doctor or psychologist. These states respond well to correction, and giving up experimental substances is the first step.

Editorial Conclusions

PPAR-delta is present in the nervous system, but the effect of GW-501516 on mood, sleep, and anxiety in humans has not been studied. Any confident statements on this topic have no scientific basis.

User complaints are most likely related to accompanying stimulants, the unknown composition of products, the diet and training regimen, and stress over health risks.

The main problem of Cardarine lies not in the psyche but in the data on carcinogenicity, which stopped its development.

We also advise reading our materials on the history of Cardarine’s development, on its interaction with other substances, and on Cardarine and bone tissue.

References

1. Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta. 2007;1771(8):1031–1045.
2. Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol. 2007;27(2):359–365.
3. Risérus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57(2):332–339.
4. Yang X, Downes M, Yu RT, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell. 2006;126(4):801–810.
5. Fan W, Waizenegger W, Lin CS, et al. PPARδ promotes running endurance by preserving glucose. Cell Metab. 2017;25(5):1186–1193.
6. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405–415.
7. World Anti-Doping Agency. Prohibited List. Montreal: WADA; чинна редакція.